BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 11283474)

  • 1. Nateglinide for type 2 diabetes.
    Med Lett Drugs Ther; 2001 Apr; 43(1101):29-30. PubMed ID: 11283474
    [No Abstract]   [Full Text] [Related]  

  • 2. [symbol: see text] Nateglinide and [symbol: see text] repaglinide for type 2 diabetes?
    Drug Ther Bull; 2003 Jul; 41(7):52-4. PubMed ID: 12879789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
    Campbell IW
    Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nateglinide may increase high-molecular weight adiponectin in type 2 diabetic patients with hypoadiponectinemia.
    Iwase M; Iino K; Doi Y; Asano T; Iida M
    Diabetes Res Clin Pract; 2008 Dec; 82(3):e19-22. PubMed ID: 18849086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis.
    Tentolouris N; Boutati E; Karambakalis N; Perrea D; Tselepis AD; Tsoukala C; Kyriaki D; Lourida E; Anastasopoulou I; Karafoullidou A; Raptis SA; Katsilambros N
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):6-12. PubMed ID: 15871845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fasting hyperglycemia and postprandial glucose peaks. Diabetes therapy mustact on 2 sides].
    MMW Fortschr Med; 2003 Aug; 145(33-34):59. PubMed ID: 14526583
    [No Abstract]   [Full Text] [Related]  

  • 7. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial.
    Dashora UK; Sibal L; Ashwell SG; Home PD
    Diabet Med; 2007 Apr; 24(4):344-9. PubMed ID: 17298589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, tolerability and safety of nateglinide in combination with metformin. Results from a study under general practice conditions.
    Schatz H; Schoppel K; Lehwalder D; Schandry R
    Exp Clin Endocrinol Diabetes; 2003 Aug; 111(5):262-6. PubMed ID: 12951631
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New drugs for diabetes.
    Tack CJ; Smits P
    Neth J Med; 1999 Nov; 55(5):209-11. PubMed ID: 10593129
    [No Abstract]   [Full Text] [Related]  

  • 10. Nateglinide (Starlix): update on a new antidiabetic agent.
    Phillips LS; Dunning BE
    Int J Clin Pract; 2003; 57(6):535-41. PubMed ID: 12918894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
    Yang JK; Wang L;
    Clin Drug Investig; 2013 Mar; 33(3):185-91. PubMed ID: 23338975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
    Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
    Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of repaglinide and nateglinide in combination with metformin: response to Raskin et al.
    Baron MA
    Diabetes Care; 2003 Dec; 26(12):3361-2; author reply 3362-3. PubMed ID: 14633839
    [No Abstract]   [Full Text] [Related]  

  • 14. Nateglinide, a new agent for postprandial glucose control in type 2 diabetes.
    Kotapati S
    Conn Med; 2002 May; 66(5):269-72. PubMed ID: 12071108
    [No Abstract]   [Full Text] [Related]  

  • 15. Glycaemic control in type 2 diabetes.
    Campbell A
    Clin Evid; 2005 Dec; (14):474-90. PubMed ID: 16620416
    [No Abstract]   [Full Text] [Related]  

  • 16. [Preclinical studies of AY4166 (A-4166)].
    Kondo N
    Nihon Rinsho; 1997 Nov; 55 Suppl():159-63. PubMed ID: 9434461
    [No Abstract]   [Full Text] [Related]  

  • 17. Restoring post-prandial insulin release in type 2 diabetes.
    Andrews J
    Hosp Med; 2002 Feb; 63(2):95-8. PubMed ID: 11902096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nateglinide: a new rapid-acting insulinotropic agent.
    Hanif W; Kumar S
    Expert Opin Pharmacother; 2001 Jun; 2(6):1027-31. PubMed ID: 11585005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-load hyperglycaemia-an inappropriate therapeutic target.
    Yudkin JS
    Lancet; 2002 Jan; 359(9301):166-7. PubMed ID: 11809285
    [No Abstract]   [Full Text] [Related]  

  • 20. [Clinical trial of AY4166].
    Kikuchi M
    Nihon Rinsho; 1997 Nov; 55 Suppl():164-70. PubMed ID: 9434462
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.